Trial Profile

Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 As a Single Agent and in Combination with Pertuzumab in Subjects with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab imbotolimod (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
Focus Therapeutic Use
Sponsors Bolt Biotherapeutics

20 Aug 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Oct 2024.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
14 May 2024 According to a Bolt Biotherapeutics media release, company has decided to discontinue development of trastuzumab imbotolimod (BDC-1001) because clinical validation for the ISAC mechanism did not meet high bar for advancement.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com